Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Glucagon-like peptide-1 (GLP-1) receptor agonistsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)along with tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist, have transformed the management of type 2 diabetes and obesity
In addition, included were, i.e., 4-week intravenous toxicity in rats followed by 4 weeks of recovery, 4-week intravenous toxicity in dogs, sub-acute (14 days) intracolonic toxicity study in rats and Beagle dogs, a repeated dose (28 days) dermal toxicity study in Wistar rats, chromosome aberrations in human lymphocytes cultured in vitro, an Ames test, a micronucleus test, female fertility and early embryonal development after intravenous administration to rats, embryofetal development after intravenous administration to rats (including toxicokinetics in pregnant animals and placental transfer), embryofetal development after intravenous administration in New Zealand White rabbits, cardiovascular and respiratory systems in anesthetized dog, a sensitization study in guinea pigs (Maximization test), and an acute eye irritation/corrosion study in albino rabbits
Proper injection techniques and hygiene should be maintained to ensure safety
Prescription orders require confirmation by your prescribing veterinarian
